Combination of | |
---|---|
Indacaterol | Ultra- long-acting beta-adrenoceptor agonist |
Glycopyrronium bromide | Muscarinic anticholinergic |
Mometasone furoate | Corticosteroid |
Clinical data | |
Trade names | Enerzair Breezhaler, Zimbus Breezhaler |
Other names | QVM149 |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Indacaterol/glycopyrronium bromide/mometasone, sold under the brand name Enerzair Breezhaler among others, is an inhalable fixed-dose combination medication for the treatment of asthma. [7] It contains indacaterol as acetate, glycopyrronium bromide, and mometasone furoate. [7]
The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat). [7] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache. [7]
It is the first asthma triple-combination therapy; it consists of a fixed-dose combination of three active substances (indacaterol, glycopyrronium bromide and mometasone furoate) in capsules, to be administered using an inhaler. [11] An optional electronic sensor may also be co-packed with the product. [11] The sensor will be attached to the base of the inhaler to collect data on the use of the inhaler by the patient. [11] The sensor will send the data to an app on a smart phone or other suitable device. [11] It was approved for medical use in the European Union in July 2020. [7] [8] [12]
Indacaterol/glycopyrronium bromide/mometasone is indicated as a maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year. [7]
Indacaterol is a long-acting beta-2 adrenergic receptor agonist. [7] It relaxes the muscle around the airways into the lungs by activating targets called beta-2 receptors in the muscle cells. [7] This helps to keep the airways open. [7]
Glycopyrronium bromide is a muscarinic receptor antagonist. [7] It blocks muscarinic receptors in muscle cells in the airways. [7] Because these receptors help control the contraction of the airway muscles, blocking them causes the muscles to relax, helping to keep the airways open. [7]
Mometasone is a corticosteroid that has anti-inflammatory effects. [7] It works in a similar way to corticosteroid hormones in the body, reducing the activity of the immune system (the body's defences). [7] Mometasone helps to keep the airways clear by blocking the release of substances, such as histamine, that are involved in inflammation and release of mucus in the airways. [7]
In April 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for Enerzair Breezhaler, a new asthma treatment which includes an optional digital sensor. [11] [13] The CHMP also recommended granting a marketing authorization in the European Union for Zimbus Breezhaler which is a duplicate of Enerzair Breezhaler. [11] [14]
Enerzair Breezhaler and Zimbus Breezhaler were approved for medical use in the European Union in July 2020. [7] [8] [12]
Combination of | |
---|---|
Indacaterol | Ultra- long-acting beta-adrenoceptor agonist |
Glycopyrronium bromide | Muscarinic anticholinergic |
Mometasone furoate | Corticosteroid |
Clinical data | |
Trade names | Enerzair Breezhaler, Zimbus Breezhaler |
Other names | QVM149 |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Indacaterol/glycopyrronium bromide/mometasone, sold under the brand name Enerzair Breezhaler among others, is an inhalable fixed-dose combination medication for the treatment of asthma. [7] It contains indacaterol as acetate, glycopyrronium bromide, and mometasone furoate. [7]
The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat). [7] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache. [7]
It is the first asthma triple-combination therapy; it consists of a fixed-dose combination of three active substances (indacaterol, glycopyrronium bromide and mometasone furoate) in capsules, to be administered using an inhaler. [11] An optional electronic sensor may also be co-packed with the product. [11] The sensor will be attached to the base of the inhaler to collect data on the use of the inhaler by the patient. [11] The sensor will send the data to an app on a smart phone or other suitable device. [11] It was approved for medical use in the European Union in July 2020. [7] [8] [12]
Indacaterol/glycopyrronium bromide/mometasone is indicated as a maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year. [7]
Indacaterol is a long-acting beta-2 adrenergic receptor agonist. [7] It relaxes the muscle around the airways into the lungs by activating targets called beta-2 receptors in the muscle cells. [7] This helps to keep the airways open. [7]
Glycopyrronium bromide is a muscarinic receptor antagonist. [7] It blocks muscarinic receptors in muscle cells in the airways. [7] Because these receptors help control the contraction of the airway muscles, blocking them causes the muscles to relax, helping to keep the airways open. [7]
Mometasone is a corticosteroid that has anti-inflammatory effects. [7] It works in a similar way to corticosteroid hormones in the body, reducing the activity of the immune system (the body's defences). [7] Mometasone helps to keep the airways clear by blocking the release of substances, such as histamine, that are involved in inflammation and release of mucus in the airways. [7]
In April 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for Enerzair Breezhaler, a new asthma treatment which includes an optional digital sensor. [11] [13] The CHMP also recommended granting a marketing authorization in the European Union for Zimbus Breezhaler which is a duplicate of Enerzair Breezhaler. [11] [14]
Enerzair Breezhaler and Zimbus Breezhaler were approved for medical use in the European Union in July 2020. [7] [8] [12]